<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Vet Sci</journal-id><journal-id journal-id-type="iso-abbrev">Vet Sci</journal-id><journal-id journal-id-type="publisher-id">vetsci</journal-id><journal-title-group><journal-title>Veterinary Sciences</journal-title></journal-title-group><issn pub-type="epub">2306-7381</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39728999</article-id><article-id pub-id-type="pmc">PMC11680090</article-id>
<article-id pub-id-type="doi">10.3390/vetsci11120659</article-id><article-id pub-id-type="publisher-id">vetsci-11-00659</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>A Universal Multi-Epitope Vaccine Design Against Porcine Reproductive and Respiratory Syndrome Virus via Bioinformatics and Immunoinformatics Approaches</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-0325-4669</contrib-id><name><surname>Lei</surname><given-names>Xinnuo</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software/">Software</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><xref rid="af1-vetsci-11-00659" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Wu</surname><given-names>Zhi</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><xref rid="af1-vetsci-11-00659" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Feng</surname><given-names>Qi</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software/">Software</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><xref rid="af1-vetsci-11-00659" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Jia</surname><given-names>Wenfeng</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af1-vetsci-11-00659" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Xie</surname><given-names>Jun</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><xref rid="af1-vetsci-11-00659" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Zhou</surname><given-names>Qingkang</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><xref rid="af1-vetsci-11-00659" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Ban</surname><given-names>Jinzhao</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><xref rid="af1-vetsci-11-00659" ref-type="aff">1</xref><xref rid="af2-vetsci-11-00659" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Zhu</surname><given-names>Shanyuan</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><xref rid="af1-vetsci-11-00659" ref-type="aff">1</xref><xref rid="c1-vetsci-11-00659" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Maes</surname><given-names>Dominiek</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-vetsci-11-00659"><label>1</label>Jiangsu Key Laboratory for High-Tech Research and Development of Veterinary Biopharmaceuticals, Engineering Technology Research Center for Modern Animal Science and Novel Veterinary Pharmaceutic Development, Jiangsu Agri-Animal Husbandry Vocational College, Taizhou 225300, China; <email>xlei@jsahvc.edu.cn</email> (X.L.); <email>zhiwu@jsahvc.edu.cn</email> (Z.W.); <email>2010010333@jsahvc.edu.cn</email> (Q.F.); <email>2022010481@jsahvc.edu.cn</email> (W.J.); <email>xjjstz2018@163.com</email> (J.X.); <email>zhouqingkang1220@126.com</email> (Q.Z.); <email>2020107040@stu.njau.edu.cn</email> (J.B.)</aff><aff id="af2-vetsci-11-00659"><label>2</label>Ministry of Agriculture Key Laboratory of Animal Bacteriology, College of Veterinary Medicine, Nanjing Agricultural University, Nanjing 210095, China</aff><author-notes><corresp id="c1-vetsci-11-00659"><label>*</label>Correspondence: <email>zsy@jsahvc.edu.cn</email></corresp></author-notes><pub-date pub-type="epub"><day>16</day><month>12</month><year>2024</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2024</year></pub-date><volume>11</volume><issue>12</issue><elocation-id>659</elocation-id><history><date date-type="received"><day>05</day><month>11</month><year>2024</year></date><date date-type="rev-recd"><day>10</day><month>12</month><year>2024</year></date><date date-type="accepted"><day>13</day><month>12</month><year>2024</year></date></history><permissions><copyright-statement>&#x000a9; 2024 by the authors.</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract abstract-type="plain-language-summary"><title>Simple Summary</title><p>Porcine reproductive and respiratory syndrome virus (PRRSV) is among the most harmful pathogens affecting the swine industry. Traditional inactivated or attenuated vaccines have proven inadequate for effective control, highlighting the need for novel, safe, and effective vaccine strategies. In this study, bioinformatics and immunoinformatics methods were used to rationally design a universal multi-epitope vaccine, which demonstrated excellent performance based on physicochemical properties, structural stability, immune receptor binding affinity, and immunogenicity. These attributes suggest that the designed vaccine holds significant promise as a novel, universal subunit vaccine candidate for preventing PRRSV infection.</p></abstract><abstract><title>Abstract</title><p>Porcine reproductive and respiratory syndrome virus (PRRSV) causes reproductive disorders in sows and severe pneumonia in piglets, alongside immunosuppressive effects on the host. It poses a significant global threat to the swine industry, with no effective control measures currently available due to its complex pathogenesis and high variability. Conventional inactivated and attenuated vaccines provide inadequate protection and carry biosafety risks. In this study, we designed a universal multi-epitope peptide vaccine against PRRSV using bioinformatics and immunoinformatics approaches to address these limitations. By selecting sequences from seven representative PRRSV strains, we predicted highly conserved and immunogenic T cell (Th and CTL) epitopes across all encoded proteins. These were rationally concatenated with reported B cell neutralizing epitopes into a multi-epitope vaccine construct. We performed comprehensive assessments of the construct&#x02019;s physicochemical and biochemical properties, along with predictions and refinements of its secondary and tertiary structures. Molecular docking simulations with TLR2 and TLR4 revealed strong potential binding interactions. Immune simulations indicated that the multi-epitope vaccine could induce robust humoral and cellular immune responses. This study provides a scientific foundation for the development of safe and effective PRRSV subunit vaccines and offers new perspectives for designing vaccines against other viral diseases.</p></abstract><kwd-group><kwd>PRRSV</kwd><kwd>multi-epitope</kwd><kwd>universal vaccine</kwd><kwd>bioinformatics</kwd><kwd>immunoinformatics</kwd></kwd-group><funding-group><award-group><funding-source>Jiangsu Agri-Animal Husbandry Vocational College</funding-source><award-id>NSF2023TC01</award-id><award-id>NSF2022CB02</award-id></award-group><award-group><funding-source>The Major Science and Technology Projects of Tibet Autonomous Region</funding-source><award-id>XZ202101ZD0005N</award-id></award-group><funding-statement>This work was supported by Jiangsu Agri-Animal Husbandry Vocational College Natural Science Project (NSF2023TC01, NSF2022CB02), and the Major Science and Technology Projects of Tibet Autonomous Region (no. XZ202101ZD0005N).</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-vetsci-11-00659"><title>1. Introduction</title><p>The swine industry constitutes a pivotal sector within the global agricultural economy, essential for food security and agricultural sustainability. However, its health and productivity are continually threatened by various pathogens that impact animal health, welfare, and the quality and safety of pork products. Porcine reproductive and respiratory syndrome virus (PRRSV), discovered nearly 40 years ago, remains one of the most challenging pathogens to control. With high variability, rapid transmission, and immunosuppressive characteristics, PRRSV causes reproductive disorders in sows and severe respiratory issues in piglets, presenting a critical concern worldwide [<xref rid="B1-vetsci-11-00659" ref-type="bibr">1</xref>,<xref rid="B2-vetsci-11-00659" ref-type="bibr">2</xref>].</p><p>PRRSV, a member of the <italic toggle="yes">Arteriviridae</italic> family and the <italic toggle="yes">Betaarterivirus</italic> genus, is divided into two species: <italic toggle="yes">Betaarterivirus suid</italic> 1 and <italic toggle="yes">Betaarterivirus suid</italic> 2 [<xref rid="B3-vetsci-11-00659" ref-type="bibr">3</xref>]. This enveloped, positive-sense single-stranded RNA virus has a ~15 kb genome encoding multiple open reading frames (ORFs). ORF1a and ORF1b encode large polyproteins pp1a and pp1ab, which are processed into at least 14 non-structural proteins (Nsps) essential for viral genome replication and transcription [<xref rid="B4-vetsci-11-00659" ref-type="bibr">4</xref>]. Additionally, PRRSV encodes eight structural proteins involved in virion assembly, infection, and immune evasion [<xref rid="B5-vetsci-11-00659" ref-type="bibr">5</xref>].</p><p>The high mutation rate of PRRSV has resulted in the emergence of numerous distinct variants, several of which serve as important reference strains in PRRSV research. For instance, the Lelystad virus (LV), the prototypical European PRRSV strain, was first identified in the Netherlands in 1991 [<xref rid="B6-vetsci-11-00659" ref-type="bibr">6</xref>]. VR-2332, a classical North American strain, was isolated in 1992 in the U.S. [<xref rid="B7-vetsci-11-00659" ref-type="bibr">7</xref>]. Early strains, such as CH-1a (identified in 1996), and highly pathogenic strains, like JXA1 (identified in 2006), which triggered outbreaks in China, serve as regional references [<xref rid="B8-vetsci-11-00659" ref-type="bibr">8</xref>]. More recently, NADC30 (identified in 2008) and NADC34 (identified in 2017) strains represent U.S. variants, with the highly pathogenic RFLP 1-4-4 lineage 1C emerging in 2020 and causing severe economic losses in the swine industry [<xref rid="B9-vetsci-11-00659" ref-type="bibr">9</xref>,<xref rid="B10-vetsci-11-00659" ref-type="bibr">10</xref>,<xref rid="B11-vetsci-11-00659" ref-type="bibr">11</xref>]. The sequences and pathogenic characteristics of these strains provide a foundation for studying PRRSV pathogenesis and advancing vaccine development.</p><p>Current commercial PRRSV vaccines, however, present notable limitations regarding safety and efficacy. Modified live vaccines (MLVs) offer partial protection but are associated with significant concerns, including virus shedding, reversion to virulence, recombination with wild-type variants, and limited cross-protection against heterologous variants [<xref rid="B12-vetsci-11-00659" ref-type="bibr">12</xref>]. Inactivated vaccines, while safer, suffer from inadequate immunogenicity [<xref rid="B13-vetsci-11-00659" ref-type="bibr">13</xref>]. Consequently, there is an urgent demand for novel vaccines that combine safety with high efficacy.</p><p>Epitope-based peptide vaccines offer a promising strategy by targeting specific pathogenic epitopes, eliminating toxic and allergenic viral components, and enabling precise immune responses against the pathogen [<xref rid="B14-vetsci-11-00659" ref-type="bibr">14</xref>]. They have been extensively utilized in the development of research targeting viral and bacterial diseases. For instance, Prakash et al. engineered a multi-epitope pan-variant SARS-CoV-2 vaccine comprising conserved human B and T cell epitopes from both structural and non-structural SARS proteins. This vaccine is capable of eliciting cross-protective immunity, facilitating viral clearance, and reducing the incidence, associated pulmonary pathology, and mortality [<xref rid="B15-vetsci-11-00659" ref-type="bibr">15</xref>]. Liu et al. employed reverse vaccinology and immunoinformatics to identify 11 conserved proteins in eight common serotypes of Streptococcus suis. They selected 16 candidate epitopes to design two promising epitope peptide vaccines, which demonstrated the potential to prevent Streptococcus suis infection in a murine model and exhibited excellent cross-protective effects [<xref rid="B16-vetsci-11-00659" ref-type="bibr">16</xref>]. The design and production of such vaccines are relatively straightforward, allowing for rapid adaptation to viral mutations and thus facilitating swift vaccine development [<xref rid="B17-vetsci-11-00659" ref-type="bibr">17</xref>]. Peptide vaccines recognized by B cells effectively enhance antibody production, while those targeting T cells stimulate a robust cellular immune response; together, these components enhance the overall immunogenicity of the vaccine [<xref rid="B18-vetsci-11-00659" ref-type="bibr">18</xref>,<xref rid="B19-vetsci-11-00659" ref-type="bibr">19</xref>].</p><p>Developing a safe and effective PRRSV vaccine remains a major challenge in veterinary medicine. While PRRSV epitope peptide vaccines show significant promise, research in this area is limited. A recent study employed immunoinformatics tools to develop a candidate vaccine incorporating B cell epitopes from the PRRSV GP3 and GP5 proteins, along with dominant protective cytotoxic T lymphocyte (CTL) and helper T lymphocyte (HTL) epitopes. However, this approach did not comprehensively address other PRRSV-encoded proteins or involve diverse variant sequences [<xref rid="B20-vetsci-11-00659" ref-type="bibr">20</xref>]. Our previous research demonstrated that linking reported PRRSV CTL epitopes with Fc molecules induced high cellular immunity in mice and prolonged the antigen half-life [<xref rid="B3-vetsci-11-00659" ref-type="bibr">3</xref>]. However, challenges remain in designing an epitope peptide vaccine that can simultaneously induce both humoral and cellular immunity and improve cross-protection against various PRRSV variants.</p><p>This study aimed to address these limitations by utilizing multiple bioinformatics tools to design a novel, universal anti-PRRSV multi-epitope peptide vaccine, optimizing it for efficacy, safety, and cross-protective potential. The design methodology in this study not only advances PRRSV vaccine development but also offers a new perspective for vaccine design against other viral diseases.</p></sec><sec id="sec2-vetsci-11-00659"><title>2. Materials and Methods</title><sec id="sec2dot1-vetsci-11-00659"><title>2.1. Acquisition and Alignment of Representative Strain Sequences</title><p>Sequences of seven representative PRRSV strains were obtained from the National Center for Biotechnology Information (NCBI) database (<uri xlink:href="https://www.ncbi.nlm.nih.gov">https://www.ncbi.nlm.nih.gov</uri>, accessed on 28 June 2024) with GenBank IDs as follows: M96262 (LV), U87392 (VR-2332), AY032626 (CH-1a), EF112445 (JXA1), MH500776 (NADC30), MF326985 (NADC34), and MW887655 (RFLP_1-4-4). Comparative analyses of genome sequences and protein identities among these strains, along with phylogenetic tree construction, were conducted using the Neighbor-Joining method in MEGA-11.</p></sec><sec id="sec2dot2-vetsci-11-00659"><title>2.2. Prediction and Selection of Antigenic Epitopes</title><p>B cell neutralizing epitopes were identified based on published studies and verified across sequences from various strains. For Th epitope prediction, we employed the Immune Epitope Database (IEDB) MHC-II Binding Predictions tool (<uri xlink:href="http://tools.iedb.org/mhcii/">http://tools.iedb.org/mhcii/</uri>, accessed on 25 July 2024), using the NetMHCIIpan 4.1 BA method with a seven-allele HLA reference set and default length. Epitope-selection criteria were set at an IC50 &#x02264; 50 nM and %Rank &#x02264; 1. CTL Epitope prediction was conducted using NetMHCcons-1.1 (<uri xlink:href="https://services.healthtech.dtu.dk/services/NetMHCcons-1.1/">https://services.healthtech.dtu.dk/services/NetMHCcons-1.1/</uri>, accessed on 26 July 2024), with the following parameters: method = NetMHCcons; species = pig; alleles = SLA-1*0401, SLA-1*0801, SLA-2*0101, SLA-2*0401, SLA-2*0502, SLA-2*1001, and SLA-3*0401; peptide length = 9. Strong binders were defined as those with an IC50 &#x02264; 50 nM and %Rank &#x02264; 0.5. BepiPred 2.0 (<uri xlink:href="http://tools.iedb.org/bcell/">http://tools.iedb.org/bcell/</uri>, accessed on 28 July 2024) was used to assess the antigenicity of different combinations of NE epitopes.</p></sec><sec id="sec2dot3-vetsci-11-00659"><title>2.3. Evaluation of Physicochemical and Biochemical Properties</title><p>Expasy-ProtParam (<uri xlink:href="https://web.expasy.org/protparam/">https://web.expasy.org/protparam/</uri>, accessed on 30 July 2024) was used to estimate the physicochemical properties of the multi-epitope vaccine, while AllerTop v2.0 evaluated allergenicity, and Protein-Sol (<uri xlink:href="https://protein-sol.manchester.ac.uk/">https://protein-sol.manchester.ac.uk/</uri>, accessed on 30 July 2024) assessed protein solubility. VaxiJen v2.0 determined antigenicity, and Class I Immunogenicity assessed the immunogenic potential. AllerTop v2.0 (<uri xlink:href="https://www.ddg-pharmfac.net/AllerTOP/method.html">https://www.ddg-pharmfac.net/AllerTOP/method.html</uri>, accessed on 30 July 2024) and ToxiPred2 (<uri xlink:href="https://webs.iiitd.edu.in/raghava/toxinpred2/batch.html">https://webs.iiitd.edu.in/raghava/toxinpred2/batch.html</uri>, accessed on 30 July 2024) further analyzed potential allergenicity and toxicity.</p></sec><sec id="sec2dot4-vetsci-11-00659"><title>2.4. Prediction, Refinement, and Validation of Protein Structure</title><p>The PSIPRED4.0 server (<uri xlink:href="http://bioinf.cs.ucl.ac.uk/psipred">http://bioinf.cs.ucl.ac.uk/psipred</uri>, accessed on 29 July 2024) was used to predict the secondary structure of the multi-epitope vaccine. Tertiary structure modeling was performed using the AlphaFold3 server (<uri xlink:href="https://alphafoldserver.com/">https://alphafoldserver.com/</uri>, accessed on 10 August 2024). GalaxyRefine (<uri xlink:href="https://galaxy.seoklab.org/cgi-bin/submit.cgi?type=REFINE">https://galaxy.seoklab.org/cgi-bin/submit.cgi?type=REFINE</uri>, accessed on 15 August 2024) refined the 3D structure. Structural quality assessment was conducted using the SWISS-MODEL server (<uri xlink:href="https://swissmodel.expasy.org/assess">https://swissmodel.expasy.org/assess</uri>, accessed on 20 August 2024) and ProSA-web (<uri xlink:href="https://prosa.services.came.sbg.ac.at/prosa.php">https://prosa.services.came.sbg.ac.at/prosa.php</uri>, accessed on 20 August 2024).</p></sec><sec id="sec2dot5-vetsci-11-00659"><title>2.5. Molecular Docking</title><p>Porcine TLR2 dimer, TLR4 dimer, SLA1, and SLA2 models were generated using AlphaFold3. Molecular docking was performed using the HDOCK server (<uri xlink:href="http://hdock.phys.hust.edu.cn/">http://hdock.phys.hust.edu.cn/</uri>, accessed on 23 August 2024), selecting the most stable model for further analysis. Docking results were visualized using PyMOL 3.1.</p></sec><sec id="sec2dot6-vetsci-11-00659"><title>2.6. Immune Response Simulation</title><p>To evaluate immune responses, C-Immune Simulation (<uri xlink:href="https://kraken.iac.rm.cnr.it/C-IMMSIM/">https://kraken.iac.rm.cnr.it/C-IMMSIM/</uri>, accessed on 10 September 2024) was used. Simulation parameters were optimized with 500 steps, administering immunizations on days 0, 28, and 70 without LPS. All other settings were set to default.</p></sec><sec id="sec2dot7-vetsci-11-00659"><title>2.7. Codon Optimization and In Silico Cloning</title><p>Codon optimization for Escherichia coli and Spodoptera frugiperda was performed using ExpOptimizer (<uri xlink:href="https://www.novopro.cn/tools/codon-optimization.html">https://www.novopro.cn/tools/codon-optimization.html</uri>, accessed on 12 September 2024), translating the multi-epitope peptide sequence into a nucleotide sequence. The vaccine gene was cloned in silico into PET-28a(+) and pFastBac1 vectors using SnapGene v5.2.</p></sec></sec><sec sec-type="results" id="sec3-vetsci-11-00659"><title>3. Results</title><sec id="sec3dot1-vetsci-11-00659"><title>3.1. Selection of Reference Strains and Conserved Sequence Analysis</title><p>To guide vaccine design, seven historically significant strains of PRRSV were selected based on sequence data obtained from GenBank, in chronological order: LV, VR-2332, CH-1a, JXA1, NADC30, NADC34, and RFLP_1-4-4. A phylogenetic tree based on whole-genome sequences (<xref rid="vetsci-11-00659-f001" ref-type="fig">Figure 1</xref>) revealed that these strains distinctly group into three major clusters, reflecting the three evolutionary phases of PRRSV. Additionally, the genomic identities of these seven strains, along with the amino acid sequence identities of their encoded proteins, are presented in <xref rid="app1-vetsci-11-00659" ref-type="app">Table S1</xref>. This foundational information is critical for identifying consensus epitope sequences for further vaccine design.</p></sec><sec id="sec3dot2-vetsci-11-00659"><title>3.2. Prediction and Selection of Epitopes</title><p>T-helper (Th) cell epitopes activate T cells, promoting cytokine secretion and enhancing immune responses. Using the IEDB MHC-II Binding Predictions tool, Th epitopes across the seven representative strains were predicted, applying a stringent threshold of IC50 &#x02264; 50 nM, percentile rank &#x02264; 1, and sequence conservation &#x02265;5/7 strains. Seven peptides meeting these criteria were selected (<xref rid="vetsci-11-00659-t001" ref-type="table">Table 1</xref>), with additional details provided in <xref rid="app1-vetsci-11-00659" ref-type="app">Table S2</xref>.</p><p>Cytotoxic T lymphocyte (CTL) epitopes, presented by MHC class I molecules, activate CD8+ T cells to trigger cellular immunity. Similar selection criteria were used for CTL epitopes, resulting in the initial identification of 65 CTL epitopes through IEDB MHC-I binding predictions. Of these, the 10 most promising CTL epitopes were selected (<xref rid="vetsci-11-00659-t002" ref-type="table">Table 2</xref>), including &#x0201c;RTAIGTPVY&#x0201d;, which has been previously reported [<xref rid="B21-vetsci-11-00659" ref-type="bibr">21</xref>].</p><p>For B cell epitopes, only neutralizing epitopes of PRRSV were retained, as non-neutralizing epitopes could potentially induce antibody-dependent enhancement (ADE). Known neutralizing epitopes include &#x0201c;SSHLQLIYNLT&#x0201d; in GP5 and &#x0201c;QAAAEVYEPGRS&#x0201d; in GP3. While neutralizing epitopes &#x0201c;WSFADGN&#x0201d; and &#x0201c;GVSAAQEKISFG&#x0201d; have been reported in GP4, sequence alignment revealed their presence solely in the LV strain (European genotype). Thirteen peptides were selected for further study based on their degree of conservation across strains (<xref rid="vetsci-11-00659-t003" ref-type="table">Table 3</xref>). The positions of all candidate epitopes within the protein amino acid sequences are indicated in <xref rid="app1-vetsci-11-00659" ref-type="app">Figures S1&#x02013;S3</xref>.</p></sec><sec id="sec3dot3-vetsci-11-00659"><title>3.3. Construction of the Multi-Epitope Vaccine (THs-CTLs-NEs)</title><p>A multi-epitope vaccine construct, designated as THs-CTLs-NEs, was designed using immunoinformatics methods and includes 534 amino acids (<xref rid="vetsci-11-00659-f002" ref-type="fig">Figure 2</xref>A). This vaccine comprises three main segments: NEs, THs, and CTLs. The TH segment consists of Th epitopes (<xref rid="vetsci-11-00659-t001" ref-type="table">Table 1</xref>), joined by &#x0201c;GPGPG&#x0201d; and &#x0201c;AAY&#x0201d; linkers. While the IEDB MHC-II binding predictions indicated a minimal impact of epitope order on binding affinity, linker adjustments were made to prevent the formation of unwanted epitopes with high binding affinity. Similarly, the CTL segment consists of the CTL epitopes (<xref rid="vetsci-11-00659-t002" ref-type="table">Table 2</xref>) joined in the same manner. NEs, which contain B cell epitopes, were linked by &#x0201c;GPGPG&#x0201d; and &#x0201c;EAAK&#x0201d; linkers. The sequence arrangement was refined using BepiPred 2.0, achieving 86% predicted B-cell epitope coverage in the NEs (<xref rid="vetsci-11-00659-f002" ref-type="fig">Figure 2</xref>B). The C-terminal TT peptide was added to enhance immunogenicity [<xref rid="B31-vetsci-11-00659" ref-type="bibr">31</xref>]. To determine the optimal order of the three main segments, the 3D structures of six possible recombinant proteins were predicted using AlphaFold3 and assessed for structural integrity with the SWISS-MODEL Structure Assessment server, resulting in the final THs-CTLs-NEs arrangement (<xref rid="app1-vetsci-11-00659" ref-type="app">Figure S4</xref>).</p><p>Biochemical assessments indicated non-allergenicity as determined by AllerTop v.2.0, with Protein-Sol predicting a solubility probability of 0.293 in <italic toggle="yes">Escherichia coli</italic> (<italic toggle="yes">E. coli</italic>). VaxiJen v2.0 produced an antigenicity score of 0.4084, classifying the vaccine as an antigen. The Class I Immunogenicity assessment yielded a score of 4.43026, suggesting high immunogenicity. AllerTOP v2.0 and ToxiPred2 both identified the multi-epitope vaccine as non-allergenic and non-toxic. Based on these physicochemical and biochemical properties, the designed multi-epitope vaccine represents a promising candidate for further development.</p></sec><sec id="sec3dot4-vetsci-11-00659"><title>3.4. Physicochemical and Biochemical Properties of the Multi-Epitope Vaccine</title><p>The physicochemical properties of the multi-epitope vaccine were estimated using Expasy-ProtParam, revealing a molecular weight of 57.11 kDa and a theoretical pI of 5.97. The instability index of 36.89 classifies the protein as stable, with a predicted half-life of more than 30 h in mammalian reticulocytes, over 20 h in yeast, and over 10 h in <italic toggle="yes">E. coli</italic>. Biochemical assessments indicated non-allergenicity as determined by AllerTop v.2.0, with Protein-Sol predicting a solubility probability of 0.293 in <italic toggle="yes">E. coli</italic>. VaxiJen v2.0 produced an antigenicity score of 0.4084, classifying the vaccine as an antigen. The Class I Immunogenicity assessment yielded a score of 4.43026, suggesting high immunogenicity. AllerTOP v2.0 and ToxiPred2 both identified the multi-epitope vaccine as non-allergenic and non-toxic. Based on these physicochemical and biochemical properties, the designed multi-epitope vaccine represents a promising candidate for further development.</p></sec><sec id="sec3dot5-vetsci-11-00659"><title>3.5. Secondary and Tertiary Structure Prediction of the Multi-Epitope Vaccine</title><p>The secondary structure of the multi-epitope vaccine was predicted using the PSIPRED server, indicating the presence of coils (48.3%), helices (39.7%), and sheets (12.0%) among the structural residues (<xref rid="vetsci-11-00659-f003" ref-type="fig">Figure 3</xref>A). Solubility assessments based on residue characteristics indicate proportions of small non-polar (45.7%), hydrophobic (16.5%), polar (25.1%), and aromatic plus cysteine residues (12.7%) (<xref rid="vetsci-11-00659-f003" ref-type="fig">Figure 3</xref>B).</p><p>To confirm the proper presentation of epitopes and structural stability, tertiary structure simulation of the THs-CTLs-NEs construct was modeled using AlphaFold3, followed by refinement via the GalaxyREFINE web server (<xref rid="vetsci-11-00659-f004" ref-type="fig">Figure 4</xref>A). Structural analysis confirmed that The THs, CTLs, and NEs segments predominantly form three distinct structural domains, each effectively displaying its respective epitopes. The SWISS-MODEL server was used for the structural assessment, and the resulting 3D model showed a MolProbity score of 0.97 and a Clash score of 0.88. The Ramachandran plot indicated that 96.8%, 0.56%, and 0.25% of residues fell within the Favored, outlier, and rotamer outlier regions, respectively (<xref rid="vetsci-11-00659-f004" ref-type="fig">Figure 4</xref>B,C). The ProSA-web Z-score of &#x02212;3.49 further validated the model&#x02019;s quality (<xref rid="vetsci-11-00659-f004" ref-type="fig">Figure 4</xref>D), indicating that the multi-epitope vaccine structure is stable.</p></sec><sec id="sec3dot6-vetsci-11-00659"><title>3.6. Molecular Docking of the Constructed Vaccine with Porcine TLR2 and TLR4</title><p>Toll-like receptors (TLRs), particularly TLR2 and TLR4, are integral to immune system functions, facilitating pathogen recognition, immune response activation, and the modulation of immune cell behavior. To explore interactions between the multi-epitope vaccine and these receptors, tertiary structures of porcine TLR4 and TLR2 dimers were constructed using AlphaFold3. Molecular docking simulations were conducted using the HDOCK server to evaluate binding interactions between the multi-epitope vaccine and TLR4 or TLR2. Visualization analysis via PyMOL identified 60 amino acid residues in monomeric TLR2 and 63 in monomeric TLR4 that likely interact within a 5.0 &#x000c5; range with 51 and 43 residues of THs-CTLs-NEs, respectively (<xref rid="vetsci-11-00659-f005" ref-type="fig">Figure 5</xref> and <xref rid="app1-vetsci-11-00659" ref-type="app">Tables S4 and S5</xref>). Notably, the interacting residues were predominantly localized within the THs and CTLs segments of the vaccine. These findings suggest that the designed multi-epitope vaccine demonstrates strong binding efficiency with TLR2 and TLR4.</p></sec><sec id="sec3dot7-vetsci-11-00659"><title>3.7. In Silico Cloning of the Vaccine Candidate</title><p>In line with Escherichia coli codon preferences, the multi-epitope peptide sequence was reverse-translated into a nucleotide sequence using the ExpOptimizer server. This produced a nucleotide sequence with a codon adaptation index (CAI) of 0.81, GC content of 58.68%, and length of 1605 bp. The vaccine gene sequence was subsequently cloned into the PET-28a(+) vector at <italic toggle="yes">BamHI</italic> and <italic toggle="yes">XhoI</italic> restriction sites using SnapGene (<xref rid="vetsci-11-00659-f006" ref-type="fig">Figure 6</xref>A). For potential eukaryotic expression, an alternative nucleotide sequence was generated based on Spodoptera frugiperda codon preferences, yielding a CAI of 0.84, GC content of 56.18%, and sequence length of 1605 bp. To aid in purification, a 6 &#x000d7; His tag was appended to the C-terminus. This eukaryotic construct was cloned into the pFastBac1 vector, also at <italic toggle="yes">BamHI</italic> and <italic toggle="yes">XhoI</italic> restriction sites (<xref rid="vetsci-11-00659-f006" ref-type="fig">Figure 6</xref>B).</p></sec><sec id="sec3dot8-vetsci-11-00659"><title>3.8. Immunogenicity Simulation of the Epitope-Based Vaccine</title><p>The ability of the vaccine to induce both humoral and cellular immune responses is crucial in combating viral infections. Using the C-ImmSim server, we evaluated the primary and secondary immune responses of the host following administration of the vaccine candidate. After optimizing the immunization schedule, high levels of B cells, Th cells, and cytotoxic T cell (TC) were observed, indicating robust immune responsiveness. <xref rid="vetsci-11-00659-f007" ref-type="fig">Figure 7</xref>A illustrates the antibody levels induced after three immunizations, with peak antibody levels reached at around day 80 post-immunization. Specific IgG levels, dominated by IgG1, reached a titer of approximately 1:100,000, while IgM titers peaked at around 1:1,125,000, with a combined IgM + IgG titer of about 1:225,000. Additionally, interferon-gamma (IFN-&#x003b3;) levels rose significantly, reaching approximately 420,000 ng/mL after the first immunization. IL-2 peaked at around 700,000 ng/mL after the second immunization (<xref rid="vetsci-11-00659-f007" ref-type="fig">Figure 7</xref>B).</p><p>Total and active B cell populations showed marked increases, peaking at approximately 780 cells/mm<sup>3</sup> and 770 cells/mm<sup>3</sup>, respectively, after the third immunization (<xref rid="vetsci-11-00659-f007" ref-type="fig">Figure 7</xref>C,D). Total Th cells and activated Th cell populations also increased significantly, reaching nearly 11,700 cells/mm<sup>3</sup> and 7600 cells/mm<sup>3</sup> after the second immunization (<xref rid="vetsci-11-00659-f007" ref-type="fig">Figure 7</xref>E,F). Additionally, the TC population rapidly increased to 1150 cells/mm<sup>3</sup> post-initial immunization (<xref rid="vetsci-11-00659-f007" ref-type="fig">Figure 7</xref>G) and remained at between 600 and 1000 cells/mm<sup>3</sup> up to day 165 (<xref rid="vetsci-11-00659-f007" ref-type="fig">Figure 7</xref>H). Collectively, these simulations suggest that the developed vaccine successfully induces a potent immune response in mammals following three doses.</p></sec></sec><sec sec-type="discussion" id="sec4-vetsci-11-00659"><title>4. Discussion</title><p>This study introduces a novel, universal multi-epitope vaccine, THs-CTLs-NEs, targeting PRRSV. Using advanced bioinformatics and immunoinformatics tools, this vaccine was designed to be non-toxic and non-allergenic, with excellent antigenicity and immunogenicity. Additionally, the vaccine demonstrated strong potential for interactions with TLR2 and TLR4 receptors, effectively stimulating both humoral and cellular immune responses. This research provides a theoretically feasible approach for the development of safe and effective PRRSV subunit vaccines, addressing the limitations of current PRRSV vaccines, such as limited protection, insufficient cross-protection, and biosafety risks. Furthermore, it offers valuable insights into the design of vaccines for other viral diseases.</p><p>Research on peptide vaccines based on PRRSV epitopes remains limited. Our previous work focused on designing multi-epitope vaccines based on a single strain, including CTL epitopes, but these lacked the ability to effectively induce humoral immunity and cross-protection [<xref rid="B3-vetsci-11-00659" ref-type="bibr">3</xref>]. Considering the high variability of PRRSV, the goal of vaccine research is to develop a universal vaccine capable of eliciting robust humoral and cellular immune responses to overcome the limitations of current commercial vaccines. In this study, we incorporated previously reported neutralizing epitopes along with corresponding epitopes from seven representative PRRSV strains, effectively reducing the risk of antibody-dependent enhancement (ADE) and enhancing broad applicability. Regarding T cell epitopes, we used epitope prediction software to analyze all coding proteins, including structural and non-structural proteins, of seven representative PRRSV strains, selecting 7 Th epitopes and 10 CTL epitopes under strict criteria. Among these, only 1 CTL epitope had been previously reported, whereas 22 CTL epitopes identified in earlier studies passed preliminary screening but failed to meet precise selection criteria [<xref rid="B3-vetsci-11-00659" ref-type="bibr">3</xref>]. Thus, the epitopes selected in this study theoretically exhibit stronger binding affinity for SLA-1 or SLA-2, indicating higher potential for practical applications. A recent study aligns with our epitope-selection strategy; it developed a multi-epitope vaccine against SARS-CoV-2, incorporating conserved B and T cell epitopes derived from both structural and non-structural viral proteins. This vaccine demonstrated the potential to induce cross-protective immunity, enhance viral elimination, and decrease infection rates [<xref rid="B15-vetsci-11-00659" ref-type="bibr">15</xref>]. Although our study does not present in vivo immunization results for PRRSV peptide vaccines, the vaccine design approach is at least theoretically sound.</p><p>The design principles of vaccines are generally based on the characteristics of prevalent viral strains. Many studies and commercialized vaccines rely on a single prevalent strain for their development. However, this approach most likely results in limited cross-protective efficacy. The novelty of our study in vaccine design lies in the selection of epitopes based on the sequences of seven representative PRRSV strains. These strains represent the most typical strains from past and current epidemics and have been extensively studied in the literature. The epitopes identified from these sequences, particularly those with high conservation, cover the corresponding epitopes of the vast majority of known PRRSV strains. Therefore, vaccines designed based on these epitopes theoretically possess significant broad protective potential. While the emergence of novel PRRSV variants in the future may pose challenges to this design, the methodology employed here can be refined and applied to future iterations of PRRSV vaccines.</p><p>In similar studies on epitope-based vaccines, the arrangement of epitopes is often achieved by linking them with commonly used linkers, such as &#x0201c;GPGPG&#x0201d;, &#x0201c;EAAK&#x0201d;, and &#x0201c;AAY&#x0201d; [<xref rid="B31-vetsci-11-00659" ref-type="bibr">31</xref>,<xref rid="B32-vetsci-11-00659" ref-type="bibr">32</xref>,<xref rid="B33-vetsci-11-00659" ref-type="bibr">33</xref>]. However, these linkers can unintentionally create non-target epitopes with high binding affinity, a frequently overlooked issue in the design of epitope-based vaccines. To address this problem, this study employed epitope-prediction software to evaluate various linkage strategies, ensuring optimal binding affinity. Additionally, we utilized a comprehensive suite of bioinformatics tools to conduct multidimensional predictions and assessments of the vaccine&#x02019;s secondary and tertiary structures. The TH, CTL, and NE segments formed relatively independent structural domains within the vaccine and demonstrated strong binding affinities for TLR2 and TLR4 receptors, particularly within the TH and CTL segments, as observed in subsequent molecular docking studies. These findings substantiate the theoretical robustness and efficacy of the multi-epitope vaccine design. Immune simulation results further revealed that the multi-epitope vaccine developed in this study could elicit strong humoral and cellular immune responses. Notably, significant enhancements were observed in IgG, IFN-&#x003b3;, IL-2, B cell populations, Th cell populations, and Tc cell populations. These indicators surpassed the results reported in similar studies [<xref rid="B32-vetsci-11-00659" ref-type="bibr">32</xref>,<xref rid="B34-vetsci-11-00659" ref-type="bibr">34</xref>,<xref rid="B35-vetsci-11-00659" ref-type="bibr">35</xref>] and maintained a strong immune response over an extended period.</p><p>Although the multi-epitope vaccine designed in this study demonstrates remarkable immunogenicity against PRRSV in silico, several challenges may arise during its production and practical applications. First, while our predicted results support the vaccine&#x02019;s potential, they do not conclusively reflect actual immunogenicity, particularly with respect to protective efficacy and cross-protection. Therefore, experimental validation is essential before clinical applications. Second, although epitope-based peptide vaccines offer advantages, such as an efficient design and high safety, they also face challenges, including a short half-life and limited delivery efficiency [<xref rid="B14-vetsci-11-00659" ref-type="bibr">14</xref>]. Potential solutions to these issues include employing sustained-release adjuvants or Fc molecules to prolong in vivo stimulation, incorporating targeting peptides or molecules to enhance delivery efficiency, or utilizing live viral vector systems [<xref rid="B3-vetsci-11-00659" ref-type="bibr">3</xref>,<xref rid="B36-vetsci-11-00659" ref-type="bibr">36</xref>,<xref rid="B37-vetsci-11-00659" ref-type="bibr">37</xref>,<xref rid="B38-vetsci-11-00659" ref-type="bibr">38</xref>]. Furthermore, the introduction of biological adjuvants may enhance the immunogenicity of epitope-based vaccines. </p><p>Nevertheless, it is undeniable that the reliability of bioinformatics and immunoinformatics tools has been validated in numerous studies, and their application in vaccine design, particularly in protein structure modeling, receptor docking, and immunoinformatics approaches, is transforming the field of vaccine development. Notable advances have been achieved in diseases, such as trypanosomiasis, tuberculosis, and SARS-CoV-2, using these methods [<xref rid="B39-vetsci-11-00659" ref-type="bibr">39</xref>,<xref rid="B40-vetsci-11-00659" ref-type="bibr">40</xref>,<xref rid="B41-vetsci-11-00659" ref-type="bibr">41</xref>]. These tools enhance vaccine stability and specificity, streamline the screening process for protective antigens from genomic data, and improve vaccine safety and efficacy predictions, making vaccine development more efficient and cost-effective. The application of bioinformatics provides essential guidance in selecting vaccine candidates and optimizing production, suggesting that future vaccine designs may become increasingly precise and efficient.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><app-group><app id="app1-vetsci-11-00659"><title>Supplementary Materials</title><p>The following supporting information can be downloaded at: <uri xlink:href="https://www.mdpi.com/article/10.3390/vetsci11120659/s1">https://www.mdpi.com/article/10.3390/vetsci11120659/s1</uri>, Figure S1: Localization of Th epitopes within PRRSV-encoded proteins, along with sequence comparisons of epitopes across seven representative strains; Figure S2: Localization of CTL epitopes within PRRSV-encoded proteins, along with sequence comparisons of epitopes across seven representative strains; Figure S3: Localization of neutralizing epitopes within PRRSV-encoded proteins, along with sequence comparisons of epitopes across seven representative strains; Figure S4: Structural simulation and assessment of six THs, CTLs, and NEs concatenation arrangements; Table S1: Comparison of genomic and encoded protein identity among seven representative strains; Table S2: Predicted binding affinities of seven candidate Th epitopes with seven HLA molecules; Table S3: Predicted binding affinities of 65 initially screened CTL epitopes with seven SLA molecules; Table S4: Receptor-ligand interface residue pairs of TLR4 and THs-CTLs-NEs protein complex; Table S5: Receptor-ligand interface residue pairs of TLR2 and THs-CTLs-NEs protein complex.</p><supplementary-material id="vetsci-11-00659-s001" position="float" content-type="local-data"><media xlink:href="vetsci-11-00659-s001.zip"/></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>Conceptualization, X.L. and S.Z.; data curation, X.L. and Z.W.; formal analysis, X.L. and Z.W.; funding acquisition, X.L. and S.Z.; investigation, X.L., Q.F., W.J., J.X., Q.Z. and J.B.; methodology, X.L. and Z.W.; project administration, S.Z.; software, X.L. and Q.F.; supervision, Z.W., Q.F. and S.Z.; validation, X.L. and W.J.; writing&#x02014;original draft preparation, X.L.; writing&#x02014;review and editing, Z.W. and W.J. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>Not applicable.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>The data presented in this study are available within the article.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><ref-list><title>References</title><ref id="B1-vetsci-11-00659"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lunney</surname><given-names>J.K.</given-names></name>
<name><surname>Fang</surname><given-names>Y.</given-names></name>
<name><surname>Ladinig</surname><given-names>A.</given-names></name>
<name><surname>Chen</surname><given-names>N.</given-names></name>
<name><surname>Li</surname><given-names>Y.</given-names></name>
<name><surname>Rowland</surname><given-names>B.</given-names></name>
<name><surname>Renukaradhya</surname><given-names>G.J.</given-names></name>
</person-group><article-title>Porcine Reproductive and Respiratory Syndrome Virus (PRRSV): Pathogenesis and Interaction with the Immune System</article-title><source>Annu. Rev. Anim. Biosci.</source><year>2016</year><volume>4</volume><fpage>129</fpage><lpage>154</lpage><pub-id pub-id-type="doi">10.1146/annurev-animal-022114-111025</pub-id><pub-id pub-id-type="pmid">26646630</pub-id>
</element-citation></ref><ref id="B2-vetsci-11-00659"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhao</surname><given-names>H.Z.</given-names></name>
<name><surname>Wang</surname><given-names>F.X.</given-names></name>
<name><surname>Han</surname><given-names>X.Y.</given-names></name>
<name><surname>Guo</surname><given-names>H.</given-names></name>
<name><surname>Liu</surname><given-names>C.Y.</given-names></name>
<name><surname>Hou</surname><given-names>L.N.</given-names></name>
<name><surname>Wang</surname><given-names>Y.X.</given-names></name>
<name><surname>Zheng</surname><given-names>H.</given-names></name>
<name><surname>Wang</surname><given-names>L.</given-names></name>
<name><surname>Wen</surname><given-names>Y.J.</given-names></name>
</person-group><article-title>Recent advances in the study of NADC34-like porcine reproductive and respiratory syndrome virus in China</article-title><source>Front. Microbiol.</source><year>2022</year><volume>13</volume><elocation-id>950402</elocation-id><pub-id pub-id-type="doi">10.3389/fmicb.2022.950402</pub-id><pub-id pub-id-type="pmid">35935186</pub-id>
</element-citation></ref><ref id="B3-vetsci-11-00659"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lei</surname><given-names>X.</given-names></name>
<name><surname>Ban</surname><given-names>J.</given-names></name>
<name><surname>Wu</surname><given-names>Z.</given-names></name>
<name><surname>Cao</surname><given-names>S.</given-names></name>
<name><surname>Zhou</surname><given-names>M.</given-names></name>
<name><surname>Zhang</surname><given-names>L.</given-names></name>
<name><surname>Zhu</surname><given-names>R.</given-names></name>
<name><surname>Lu</surname><given-names>H.</given-names></name>
<name><surname>Zhu</surname><given-names>S.</given-names></name>
</person-group><article-title>Boosting PRRSV-Specific Cellular Immunity: The Immunological Profiling of an Fc-Fused Multi-CTL Epitope Vaccine in Mice</article-title><source>Vet. Sci.</source><year>2024</year><volume>11</volume><elocation-id>274</elocation-id><pub-id pub-id-type="doi">10.3390/vetsci11060274</pub-id><pub-id pub-id-type="pmid">38922021</pub-id>
</element-citation></ref><ref id="B4-vetsci-11-00659"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ruedas-Torres</surname><given-names>I.</given-names></name>
<name><surname>Rodr&#x000ed;guez-G&#x000f3;mez</surname><given-names>I.M.</given-names></name>
<name><surname>S&#x000e1;nchez-Carvajal</surname><given-names>J.M.</given-names></name>
<name><surname>Larenas-Mu&#x000f1;oz</surname><given-names>F.</given-names></name>
<name><surname>Pallar&#x000e9;s</surname><given-names>F.J.</given-names></name>
<name><surname>Carrasco</surname><given-names>L.</given-names></name>
<name><surname>G&#x000f3;mez-Laguna</surname><given-names>J.</given-names></name>
</person-group><article-title>The jigsaw of PRRSV virulence</article-title><source>Vet. Microbiol.</source><year>2021</year><volume>260</volume><elocation-id>109168</elocation-id><pub-id pub-id-type="doi">10.1016/j.vetmic.2021.109168</pub-id><pub-id pub-id-type="pmid">34246042</pub-id>
</element-citation></ref><ref id="B5-vetsci-11-00659"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>X.</given-names></name>
<name><surname>Chen</surname><given-names>Y.</given-names></name>
<name><surname>Liu</surname><given-names>M.</given-names></name>
<name><surname>Long</surname><given-names>X.</given-names></name>
<name><surname>Guo</surname><given-names>C.</given-names></name>
</person-group><article-title>Intervention strategies targeting virus and host factors against porcine reproductive and respiratory syndrome virus: A systematic review</article-title><source>Int. J. Biol. Macromol.</source><year>2024</year><volume>279</volume><elocation-id>135403</elocation-id><pub-id pub-id-type="doi">10.1016/j.ijbiomac.2024.135403</pub-id><pub-id pub-id-type="pmid">39245101</pub-id>
</element-citation></ref><ref id="B6-vetsci-11-00659"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Stadejek</surname><given-names>T.</given-names></name>
<name><surname>Stankevicius</surname><given-names>A.</given-names></name>
<name><surname>Murtaugh</surname><given-names>M.P.</given-names></name>
<name><surname>Oleksiewicz</surname><given-names>M.B.</given-names></name>
</person-group><article-title>Molecular evolution of PRRSV in Europe: Current state of play</article-title><source>Vet. Microbiol.</source><year>2013</year><volume>165</volume><fpage>21</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1016/j.vetmic.2013.02.029</pub-id><pub-id pub-id-type="pmid">23528651</pub-id>
</element-citation></ref><ref id="B7-vetsci-11-00659"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Benfield</surname><given-names>D.A.</given-names></name>
<name><surname>Nelson</surname><given-names>E.</given-names></name>
<name><surname>Collins</surname><given-names>J.E.</given-names></name>
<name><surname>Harris</surname><given-names>L.</given-names></name>
<name><surname>Goyal</surname><given-names>S.M.</given-names></name>
<name><surname>Robison</surname><given-names>D.</given-names></name>
<name><surname>Christianson</surname><given-names>W.T.</given-names></name>
<name><surname>Morrison</surname><given-names>R.B.</given-names></name>
<name><surname>Gorcyca</surname><given-names>D.</given-names></name>
<name><surname>Chladek</surname><given-names>D.</given-names></name>
</person-group><article-title>Characterization of swine infertility and respiratory syndrome (SIRS) virus (isolate ATCC VR-2332)</article-title><source>J. Vet. Diagn. Invest.</source><year>1992</year><volume>4</volume><fpage>127</fpage><lpage>133</lpage><pub-id pub-id-type="doi">10.1177/104063879200400202</pub-id><pub-id pub-id-type="pmid">1616976</pub-id>
</element-citation></ref><ref id="B8-vetsci-11-00659"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhou</surname><given-names>L.</given-names></name>
<name><surname>Han</surname><given-names>J.</given-names></name>
<name><surname>Yang</surname><given-names>H.</given-names></name>
</person-group><article-title>The evolution and diversity of porcine reproductive and respiratory syndrome virus in China</article-title><source>Vet. Microbiol.</source><year>2024</year><volume>298</volume><elocation-id>110252</elocation-id><pub-id pub-id-type="doi">10.1016/j.vetmic.2024.110252</pub-id><pub-id pub-id-type="pmid">39299012</pub-id>
</element-citation></ref><ref id="B9-vetsci-11-00659"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sun</surname><given-names>Y.F.</given-names></name>
<name><surname>Liu</surname><given-names>Y.</given-names></name>
<name><surname>Yang</surname><given-names>J.</given-names></name>
<name><surname>Li</surname><given-names>W.Z.</given-names></name>
<name><surname>Yu</surname><given-names>X.X.</given-names></name>
<name><surname>Wang</surname><given-names>S.Y.</given-names></name>
<name><surname>Li</surname><given-names>L.A.</given-names></name>
<name><surname>Yu</surname><given-names>H.</given-names></name>
</person-group><article-title>Recombination between NADC34-like and QYYZ-like strain of porcine reproductive and respiratory syndrome virus with high pathogenicity for piglets in China</article-title><source>Transbound. Emerg. Dis.</source><year>2022</year><volume>69</volume><fpage>e3202</fpage><lpage>e3207</lpage><pub-id pub-id-type="doi">10.1111/tbed.14471</pub-id><pub-id pub-id-type="pmid">35119777</pub-id>
</element-citation></ref><ref id="B10-vetsci-11-00659"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jiao</surname><given-names>S.</given-names></name>
<name><surname>Zhang</surname><given-names>J.</given-names></name>
<name><surname>Wang</surname><given-names>J.</given-names></name>
<name><surname>Ma</surname><given-names>X.</given-names></name>
<name><surname>Li</surname><given-names>G.</given-names></name>
<name><surname>Li</surname><given-names>J.</given-names></name>
<name><surname>Cui</surname><given-names>Z.</given-names></name>
<name><surname>Li</surname><given-names>D.</given-names></name>
<name><surname>Li</surname><given-names>P.</given-names></name>
<name><surname>Zeng</surname><given-names>Q.</given-names></name>
<etal/>
</person-group><article-title>Whole-genome analysis of the recombination and evolution of newly identified NADC30-like porcine reproductive and respiratory syndrome virus strains circulated in Gansu province of China in 2023</article-title><source>Front. Vet. Sci.</source><year>2024</year><volume>11</volume><fpage>1372032</fpage><pub-id pub-id-type="doi">10.3389/fvets.2024.1372032</pub-id><pub-id pub-id-type="pmid">38681852</pub-id>
</element-citation></ref><ref id="B11-vetsci-11-00659"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kikuti</surname><given-names>M.</given-names></name>
<name><surname>Paploski</surname><given-names>I.A.D.</given-names></name>
<name><surname>Pamornchainavakul</surname><given-names>N.</given-names></name>
<name><surname>Picasso-Risso</surname><given-names>C.</given-names></name>
<name><surname>Schwartz</surname><given-names>M.</given-names></name>
<name><surname>Yeske</surname><given-names>P.</given-names></name>
<name><surname>Leuwerke</surname><given-names>B.</given-names></name>
<name><surname>Bruner</surname><given-names>L.</given-names></name>
<name><surname>Murray</surname><given-names>D.</given-names></name>
<name><surname>Roggow</surname><given-names>B.D.</given-names></name>
<etal/>
</person-group><article-title>Emergence of a New Lineage 1C Variant of Porcine Reproductive and Respiratory Syndrome Virus 2 in the United States</article-title><source>Front. Vet. Sci.</source><year>2021</year><volume>8</volume><elocation-id>752938</elocation-id><pub-id pub-id-type="doi">10.3389/fvets.2021.752938</pub-id><pub-id pub-id-type="pmid">34733906</pub-id>
</element-citation></ref><ref id="B12-vetsci-11-00659"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Renukaradhya</surname><given-names>G.J.</given-names></name>
<name><surname>Meng</surname><given-names>X.J.</given-names></name>
<name><surname>Calvert</surname><given-names>J.G.</given-names></name>
<name><surname>Roof</surname><given-names>M.</given-names></name>
<name><surname>Lager</surname><given-names>K.M.</given-names></name>
</person-group><article-title>Live porcine reproductive and respiratory syndrome virus vaccines: Current status and future direction</article-title><source>Vaccine</source><year>2015</year><volume>33</volume><fpage>4069</fpage><lpage>4080</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2015.06.092</pub-id><pub-id pub-id-type="pmid">26148878</pub-id>
</element-citation></ref><ref id="B13-vetsci-11-00659"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Renukaradhya</surname><given-names>G.J.</given-names></name>
<name><surname>Meng</surname><given-names>X.J.</given-names></name>
<name><surname>Calvert</surname><given-names>J.G.</given-names></name>
<name><surname>Roof</surname><given-names>M.</given-names></name>
<name><surname>Lager</surname><given-names>K.M.</given-names></name>
</person-group><article-title>Inactivated and subunit vaccines against porcine reproductive and respiratory syndrome: Current status and future direction</article-title><source>Vaccine</source><year>2015</year><volume>33</volume><fpage>3065</fpage><lpage>3072</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2015.04.102</pub-id><pub-id pub-id-type="pmid">25980425</pub-id>
</element-citation></ref><ref id="B14-vetsci-11-00659"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Malonis</surname><given-names>R.J.</given-names></name>
<name><surname>Lai</surname><given-names>J.R.</given-names></name>
<name><surname>Vergnolle</surname><given-names>O.</given-names></name>
</person-group><article-title>Peptide-Based Vaccines: Current Progress and Future Challenges</article-title><source>Chem. Rev.</source><year>2020</year><volume>120</volume><fpage>3210</fpage><lpage>3229</lpage><pub-id pub-id-type="doi">10.1021/acs.chemrev.9b00472</pub-id><pub-id pub-id-type="pmid">31804810</pub-id>
</element-citation></ref><ref id="B15-vetsci-11-00659"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Prakash</surname><given-names>S.</given-names></name>
<name><surname>Dhanushkodi</surname><given-names>N.R.</given-names></name>
<name><surname>Zayou</surname><given-names>L.</given-names></name>
<name><surname>Ibraim</surname><given-names>I.C.</given-names></name>
<name><surname>Quadiri</surname><given-names>A.</given-names></name>
<name><surname>Coulon</surname><given-names>P.G.</given-names></name>
<name><surname>Tifrea</surname><given-names>D.F.</given-names></name>
<name><surname>Suzer</surname><given-names>B.</given-names></name>
<name><surname>Shaik</surname><given-names>A.M.</given-names></name>
<name><surname>Chilukuri</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>Cross-protection induced by highly conserved human B, CD4+, and CD8+ T-cell epitopes-based vaccine against severe infection, disease, and death caused by multiple SARS-CoV-2 variants of concern</article-title><source>Front. Immunol.</source><year>2024</year><volume>15</volume><elocation-id>1328905</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2024.1328905</pub-id><pub-id pub-id-type="pmid">38318166</pub-id>
</element-citation></ref><ref id="B16-vetsci-11-00659"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>J.</given-names></name>
<name><surname>Zhang</surname><given-names>Z.</given-names></name>
<name><surname>Pu</surname><given-names>W.</given-names></name>
<name><surname>Pan</surname><given-names>X.</given-names></name>
<name><surname>Li</surname><given-names>P.</given-names></name>
<name><surname>Bai</surname><given-names>Q.</given-names></name>
<name><surname>Liang</surname><given-names>S.</given-names></name>
<name><surname>Li</surname><given-names>C.</given-names></name>
<name><surname>Yu</surname><given-names>Y.</given-names></name>
<name><surname>Yao</surname><given-names>H.</given-names></name>
<etal/>
</person-group><article-title>A multi-epitope subunit vaccine providing broad cross-protection against diverse serotypes of Streptococcus suis</article-title><source>NPJ Vaccines</source><year>2024</year><volume>9</volume><fpage>216</fpage><pub-id pub-id-type="doi">10.1038/s41541-024-01015-7</pub-id><pub-id pub-id-type="pmid">39543108</pub-id>
</element-citation></ref><ref id="B17-vetsci-11-00659"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Parvizpour</surname><given-names>S.</given-names></name>
<name><surname>Pourseif</surname><given-names>M.M.</given-names></name>
<name><surname>Razmara</surname><given-names>J.</given-names></name>
<name><surname>Rafi</surname><given-names>M.A.</given-names></name>
<name><surname>Omidi</surname><given-names>Y.</given-names></name>
</person-group><article-title>Epitope-based vaccine design: A comprehensive overview of bioinformatics approaches</article-title><source>Drug Discov. Today</source><year>2020</year><volume>25</volume><fpage>1034</fpage><lpage>1042</lpage><pub-id pub-id-type="doi">10.1016/j.drudis.2020.03.006</pub-id><pub-id pub-id-type="pmid">32205198</pub-id>
</element-citation></ref><ref id="B18-vetsci-11-00659"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cao</surname><given-names>Q.M.</given-names></name>
<name><surname>Tian</surname><given-names>D.</given-names></name>
<name><surname>Heffron</surname><given-names>C.L.</given-names></name>
<name><surname>Subramaniam</surname><given-names>S.</given-names></name>
<name><surname>Opriessnig</surname><given-names>T.</given-names></name>
<name><surname>Foss</surname><given-names>D.L.</given-names></name>
<name><surname>Calvert</surname><given-names>J.G.</given-names></name>
<name><surname>Meng</surname><given-names>X.-J.</given-names></name>
</person-group><article-title>Cytotoxic T lymphocyte epitopes identified from a contemporary strain of porcine reproductive and respiratory syndrome virus enhance CD4+CD8+ T, CD8+ T, and &#x003b3;&#x003b4; T cell responses</article-title><source>Virology</source><year>2019</year><volume>538</volume><fpage>35</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2019.09.006</pub-id><pub-id pub-id-type="pmid">31561059</pub-id>
</element-citation></ref><ref id="B19-vetsci-11-00659"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>C.Y.</given-names></name>
<name><surname>Peng</surname><given-names>W.J.</given-names></name>
<name><surname>Kuo</surname><given-names>B.S.</given-names></name>
<name><surname>Ho</surname><given-names>Y.H.</given-names></name>
<name><surname>Wang</surname><given-names>M.S.</given-names></name>
<name><surname>Yang</surname><given-names>Y.T.</given-names></name>
<name><surname>Chang</surname><given-names>P.Y.</given-names></name>
<name><surname>Shen</surname><given-names>Y.H.</given-names></name>
<name><surname>Hwang</surname><given-names>K.P.</given-names></name>
</person-group><article-title>Toward a pan-SARS-CoV-2 vaccine targeting conserved epitopes on spike and non-spike proteins for potent, broad and durable immune responses</article-title><source>PLoS Pathog.</source><year>2023</year><volume>19</volume><elocation-id>e1010870</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1010870</pub-id><pub-id pub-id-type="pmid">37079651</pub-id>
</element-citation></ref><ref id="B20-vetsci-11-00659"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>D.</given-names></name>
<name><surname>Chen</surname><given-names>Y.</given-names></name>
</person-group><article-title>Epitope screening and vaccine molecule design of PRRSV GP3 and GP5 protein based on immunoinformatics</article-title><source>J. Cell Mol. Med.</source><year>2024</year><volume>28</volume><fpage>e18103</fpage><pub-id pub-id-type="doi">10.1111/jcmm.18103</pub-id><pub-id pub-id-type="pmid">38217314</pub-id>
</element-citation></ref><ref id="B21-vetsci-11-00659"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gao</surname><given-names>C.</given-names></name>
<name><surname>He</surname><given-names>X.</given-names></name>
<name><surname>Quan</surname><given-names>J.</given-names></name>
<name><surname>Jiang</surname><given-names>Q.</given-names></name>
<name><surname>Lin</surname><given-names>H.</given-names></name>
<name><surname>Chen</surname><given-names>H.</given-names></name>
<name><surname>Qu</surname><given-names>L.</given-names></name>
</person-group><article-title>Specificity Characterization of SLA Class I Molecules Binding to Swine-Origin Viral Cytotoxic T Lymphocyte Epitope Peptides In Vitro</article-title><source>Front. Microbiol.</source><year>2017</year><volume>8</volume><elocation-id>2524</elocation-id><pub-id pub-id-type="doi">10.3389/fmicb.2017.02524</pub-id><pub-id pub-id-type="pmid">29326671</pub-id>
</element-citation></ref><ref id="B22-vetsci-11-00659"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jung</surname><given-names>B.K.</given-names></name>
<name><surname>Kim</surname><given-names>H.R.</given-names></name>
<name><surname>Jang</surname><given-names>H.</given-names></name>
<name><surname>Chang</surname><given-names>K.S.</given-names></name>
</person-group><article-title>Replacing the decoy epitope of PCV2 capsid protein with epitopes of GP3 and/or GP5 of PRRSV enhances the immunogenicity of bivalent vaccines in mice</article-title><source>J. Virol. Methods.</source><year>2020</year><volume>284</volume><fpage>113928</fpage><pub-id pub-id-type="doi">10.1016/j.jviromet.2020.113928</pub-id><pub-id pub-id-type="pmid">32650038</pub-id>
</element-citation></ref><ref id="B23-vetsci-11-00659"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pi&#x000f1;eyro</surname><given-names>P.E.</given-names></name>
<name><surname>Kenney</surname><given-names>S.P.</given-names></name>
<name><surname>Gim&#x000e9;nez-Lirola</surname><given-names>L.G.</given-names></name>
<name><surname>Heffron</surname><given-names>C.L.</given-names></name>
<name><surname>Matzinger</surname><given-names>S.R.</given-names></name>
<name><surname>Opriessnig</surname><given-names>T.</given-names></name>
<name><surname>Meng</surname><given-names>X.J.</given-names></name>
</person-group><article-title>Expression of antigenic epitopes of porcine reproductive and respiratory syndrome virus (PRRSV) in a modified live-attenuated porcine circovirus type 2 (PCV2) vaccine virus (PCV1-2a) as a potential bivalent vaccine against both PCV2 and PRRSV</article-title><source>Virus Res.</source><year>2015</year><volume>210</volume><fpage>154</fpage><lpage>164</lpage><pub-id pub-id-type="doi">10.1016/j.virusres.2015.07.027</pub-id><pub-id pub-id-type="pmid">26239318</pub-id>
</element-citation></ref><ref id="B24-vetsci-11-00659"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Plagemann</surname><given-names>P.G.</given-names></name>
</person-group><article-title>GP5 ectodomain epitope of porcine reproductive and respiratory syndrome virus, strain Lelystad virus</article-title><source>Virus Res.</source><year>2004</year><volume>102</volume><fpage>225</fpage><lpage>230</lpage><pub-id pub-id-type="doi">10.1016/j.virusres.2004.01.031</pub-id><pub-id pub-id-type="pmid">15084406</pub-id>
</element-citation></ref><ref id="B25-vetsci-11-00659"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Plagemann</surname><given-names>P.G.</given-names></name>
<name><surname>Rowland</surname><given-names>R.R.</given-names></name>
<name><surname>Faaberg</surname><given-names>K.S.</given-names></name>
</person-group><article-title>The primary neutralization epitope of porcine respiratory and reproductive syndrome virus strain VR-2332 is located in the middle of the GP5 ectodomain</article-title><source>Arch. Virol.</source><year>2002</year><volume>147</volume><fpage>2327</fpage><lpage>2347</lpage><pub-id pub-id-type="doi">10.1007/s00705-002-0887-2</pub-id><pub-id pub-id-type="pmid">12491101</pub-id>
</element-citation></ref><ref id="B26-vetsci-11-00659"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ostrowski</surname><given-names>M.</given-names></name>
<name><surname>Galeota</surname><given-names>J.A.</given-names></name>
<name><surname>Jar</surname><given-names>A.M.</given-names></name>
<name><surname>Platt</surname><given-names>K.B.</given-names></name>
<name><surname>Osorio</surname><given-names>F.A.</given-names></name>
<name><surname>Lopez</surname><given-names>O.J.</given-names></name>
</person-group><article-title>Identification of neutralizing and nonneutralizing epitopes in the porcine reproductive and respiratory syndrome virus GP5 ectodomain</article-title><source>J. Virol.</source><year>2002</year><volume>76</volume><fpage>4241</fpage><lpage>4250</lpage><pub-id pub-id-type="doi">10.1128/JVI.76.9.4241-4250.2002</pub-id><pub-id pub-id-type="pmid">11932389</pub-id>
</element-citation></ref><ref id="B27-vetsci-11-00659"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wissink</surname><given-names>E.H.J.</given-names></name>
<name><surname>van Wijk</surname><given-names>H.A.R.</given-names></name>
<name><surname>Kroese</surname><given-names>M.V.</given-names></name>
<name><surname>Weiland</surname><given-names>E.</given-names></name>
<name><surname>Meulenberg</surname><given-names>J.J.M.</given-names></name>
<name><surname>Rottier</surname><given-names>P.J.M.</given-names></name>
<name><surname>van Rijn</surname><given-names>P.A.</given-names></name>
</person-group><article-title>The major envelope protein, GP5, of a European porcine reproductive and respiratory syndrome virus contains a neutralization epitope in its N-terminal ectodomain</article-title><source>J. Gen. Virol.</source><year>2003</year><volume>84</volume><fpage>1535</fpage><lpage>1543</lpage><pub-id pub-id-type="doi">10.1099/vir.0.18957-0</pub-id><pub-id pub-id-type="pmid">12771423</pub-id>
</element-citation></ref><ref id="B28-vetsci-11-00659"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Costers</surname><given-names>S.</given-names></name>
<name><surname>Lefebvre</surname><given-names>D.J.</given-names></name>
<name><surname>Van Doorsselaere</surname><given-names>J.</given-names></name>
<name><surname>Vanhee</surname><given-names>M.</given-names></name>
<name><surname>Delputte</surname><given-names>P.L.</given-names></name>
<name><surname>Nauwynck</surname><given-names>H.J.</given-names></name>
</person-group><article-title>GP4 of porcine reproductive and respiratory syndrome virus contains a neutralizing epitope that is susceptible to immunoselection in vitro</article-title><source>Arch. Virol.</source><year>2010</year><volume>155</volume><fpage>371</fpage><lpage>378</lpage><pub-id pub-id-type="doi">10.1007/s00705-009-0582-7</pub-id><pub-id pub-id-type="pmid">20052599</pub-id>
</element-citation></ref><ref id="B29-vetsci-11-00659"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vanhee</surname><given-names>M.</given-names></name>
<name><surname>Costers</surname><given-names>S.</given-names></name>
<name><surname>Van Breedam</surname><given-names>W.</given-names></name>
<name><surname>Geldhof</surname><given-names>M.F.</given-names></name>
<name><surname>Van Doorsselaere</surname><given-names>J.</given-names></name>
<name><surname>Nauwynck</surname><given-names>H.J.</given-names></name>
</person-group><article-title>A variable region in GP4 of European-type porcine reproductive and respiratory syndrome virus induces neutralizing antibodies against homologous but not heterologous virus strains</article-title><source>Viral Immunol.</source><year>2010</year><volume>23</volume><fpage>403</fpage><lpage>413</lpage><pub-id pub-id-type="doi">10.1089/vim.2010.0025</pub-id><pub-id pub-id-type="pmid">20712485</pub-id>
</element-citation></ref><ref id="B30-vetsci-11-00659"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Van Breedam</surname><given-names>W.</given-names></name>
<name><surname>Costers</surname><given-names>S.</given-names></name>
<name><surname>Vanhee</surname><given-names>M.</given-names></name>
<name><surname>Gagnon</surname><given-names>C.A.</given-names></name>
<name><surname>Rodr&#x000ed;guez-G&#x000f3;mez</surname><given-names>I.M.</given-names></name>
<name><surname>Geldhof</surname><given-names>M.</given-names></name>
<name><surname>Verbeeck</surname><given-names>M.</given-names></name>
<name><surname>Van Doorsselaere</surname><given-names>J.</given-names></name>
<name><surname>Karniychuk</surname><given-names>U.</given-names></name>
<name><surname>Nauwynck</surname><given-names>H.J.</given-names></name>
</person-group><article-title>Porcine reproductive and respiratory syndrome virus (PRRSV)-specific mAbs: Supporting diagnostics and providing new insights into the antigenic properties of the virus</article-title><source>Vet. Immunol. Immunopathol.</source><year>2011</year><volume>141</volume><fpage>246</fpage><lpage>257</lpage><pub-id pub-id-type="doi">10.1016/j.vetimm.2011.03.008</pub-id><pub-id pub-id-type="pmid">21470695</pub-id>
</element-citation></ref><ref id="B31-vetsci-11-00659"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bai</surname><given-names>Y.</given-names></name>
<name><surname>Zhou</surname><given-names>M.</given-names></name>
<name><surname>Wang</surname><given-names>N.</given-names></name>
<name><surname>Yang</surname><given-names>Y.</given-names></name>
<name><surname>Wang</surname><given-names>D.</given-names></name>
</person-group><article-title>Designing a Candidate Multi-Epitope Vaccine against Transmissible Gastroenteritis Virus Based on Immunoinformatic and Molecular Dynamics</article-title><source>Int. J. Mol. Sci.</source><year>2024</year><elocation-id>25</elocation-id><pub-id pub-id-type="doi">10.3390/ijms25168828</pub-id><pub-id pub-id-type="pmid">39201514</pub-id>
</element-citation></ref><ref id="B32-vetsci-11-00659"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>Y.</given-names></name>
<name><surname>Zhao</surname><given-names>G.</given-names></name>
<name><surname>Xiong</surname><given-names>Y.</given-names></name>
<name><surname>Li</surname><given-names>F.</given-names></name>
<name><surname>Chen</surname><given-names>Y.</given-names></name>
<name><surname>Cheng</surname><given-names>Y.</given-names></name>
<name><surname>Ma</surname><given-names>J.</given-names></name>
<name><surname>Wang</surname><given-names>H.</given-names></name>
<name><surname>Yan</surname><given-names>Y.</given-names></name>
<name><surname>Wang</surname><given-names>Z.</given-names></name>
<etal/>
</person-group><article-title>Development of a Universal Multi-Epitope Vaccine Candidate against Streptococcus suis Infections Using Immunoinformatics Approaches</article-title><source>Vet. Sci.</source><year>2023</year><volume>10</volume><elocation-id>383</elocation-id><pub-id pub-id-type="doi">10.3390/vetsci10060383</pub-id><pub-id pub-id-type="pmid">37368769</pub-id>
</element-citation></ref><ref id="B33-vetsci-11-00659"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mahmoodi</surname><given-names>S.</given-names></name>
<name><surname>Amirzakaria</surname><given-names>J.Z.</given-names></name>
<name><surname>Ghasemian</surname><given-names>A.</given-names></name>
</person-group><article-title>In silico design and validation of a novel multi-epitope vaccine candidate against structural proteins of Chikungunya virus using comprehensive immunoinformatics analyses</article-title><source>PLoS ONE</source><year>2023</year><volume>18</volume><elocation-id>e0285177</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0285177</pub-id><pub-id pub-id-type="pmid">37146081</pub-id>
</element-citation></ref><ref id="B34-vetsci-11-00659"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhu</surname><given-names>F.</given-names></name>
<name><surname>Tan</surname><given-names>C.</given-names></name>
<name><surname>Li</surname><given-names>C.</given-names></name>
<name><surname>Ma</surname><given-names>S.</given-names></name>
<name><surname>Wen</surname><given-names>H.</given-names></name>
<name><surname>Yang</surname><given-names>H.</given-names></name>
<name><surname>Rao</surname><given-names>M.</given-names></name>
<name><surname>Zhang</surname><given-names>P.</given-names></name>
<name><surname>Peng</surname><given-names>W.</given-names></name>
<name><surname>Cui</surname><given-names>Y.</given-names></name>
<etal/>
</person-group><article-title>Design of a multi-epitope vaccine against six Nocardia species based on reverse vaccinology combined with immunoinformatics</article-title><source>Front. Immunol.</source><year>2023</year><volume>14</volume><elocation-id>1100188</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2023.1100188</pub-id><pub-id pub-id-type="pmid">36845087</pub-id>
</element-citation></ref><ref id="B35-vetsci-11-00659"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Huang</surname><given-names>S.</given-names></name>
<name><surname>Zhang</surname><given-names>C.</given-names></name>
<name><surname>Li</surname><given-names>J.</given-names></name>
<name><surname>Dai</surname><given-names>Z.</given-names></name>
<name><surname>Huang</surname><given-names>J.</given-names></name>
<name><surname>Deng</surname><given-names>F.</given-names></name>
<name><surname>Wang</surname><given-names>X.</given-names></name>
<name><surname>Yue</surname><given-names>X.</given-names></name>
<name><surname>Hu</surname><given-names>X.</given-names></name>
<name><surname>Li</surname><given-names>Y.</given-names></name>
<etal/>
</person-group><article-title>Designing a multi-epitope vaccine against coxsackievirus B based on immunoinformatics approaches</article-title><source>Front. Immunol.</source><year>2022</year><volume>13</volume><elocation-id>933594</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2022.933594</pub-id><pub-id pub-id-type="pmid">36439191</pub-id>
</element-citation></ref><ref id="B36-vetsci-11-00659"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>X.</given-names></name>
<name><surname>Zhou</surname><given-names>X.</given-names></name>
<name><surname>Noor</surname><given-names>A.U.</given-names></name>
<name><surname>Zhang</surname><given-names>X.</given-names></name>
<name><surname>Song</surname><given-names>C.</given-names></name>
<name><surname>Sun</surname><given-names>H.</given-names></name>
</person-group><article-title>Enhancing half-life and cytotoxicity of porcine respiratory and reproductive syndrome virus soluble receptors by taming their Fc domains</article-title><source>Vet. Microbiol.</source><year>2022</year><volume>273</volume><elocation-id>109526</elocation-id><pub-id pub-id-type="doi">10.1016/j.vetmic.2022.109526</pub-id><pub-id pub-id-type="pmid">35988378</pub-id>
</element-citation></ref><ref id="B37-vetsci-11-00659"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rath</surname><given-names>T.</given-names></name>
<name><surname>Baker</surname><given-names>K.</given-names></name>
<name><surname>Dumont</surname><given-names>J.A.</given-names></name>
<name><surname>Peters</surname><given-names>R.T.</given-names></name>
<name><surname>Jiang</surname><given-names>H.</given-names></name>
<name><surname>Qiao</surname><given-names>S.W.</given-names></name>
<name><surname>Lencer</surname><given-names>W.I.</given-names></name>
<name><surname>Pierce</surname><given-names>G.F.</given-names></name>
<name><surname>Blumberg</surname><given-names>R.S.</given-names></name>
</person-group><article-title>Fc-fusion proteins and FcRn: Structural insights for longer-lasting and more effective therapeutics</article-title><source>Crit. Rev. Biotechnol.</source><year>2015</year><volume>35</volume><fpage>235</fpage><lpage>254</lpage><pub-id pub-id-type="doi">10.3109/07388551.2013.834293</pub-id><pub-id pub-id-type="pmid">24156398</pub-id>
</element-citation></ref><ref id="B38-vetsci-11-00659"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Melgoza-Gonz&#x000e1;lez</surname><given-names>E.A.</given-names></name>
<name><surname>Bustamante-C&#x000f3;rdova</surname><given-names>L.</given-names></name>
<name><surname>Hern&#x000e1;ndez</surname><given-names>J.</given-names></name>
</person-group><article-title>Recent advances in antigen targeting to antigen-presenting cells in veterinary medicine</article-title><source>Front. Immunol.</source><year>2023</year><volume>14</volume><elocation-id>1080238</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2023.1080238</pub-id><pub-id pub-id-type="pmid">36969203</pub-id>
</element-citation></ref><ref id="B39-vetsci-11-00659"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Danazumi</surname><given-names>A.U.</given-names></name>
<name><surname>Iliyasu Gital</surname><given-names>S.</given-names></name>
<name><surname>Idris</surname><given-names>S.</given-names></name>
<name><surname>Bs Dibba</surname><given-names>L.</given-names></name>
<name><surname>Balogun</surname><given-names>E.O.</given-names></name>
<name><surname>G&#x000f3;rna</surname><given-names>M.W.</given-names></name>
</person-group><article-title>Immunoinformatic design of a putative multi-epitope vaccine candidate against Trypanosoma brucei gambiense</article-title><source>Comput. Struct. Biotechnol. J.</source><year>2022</year><volume>20</volume><fpage>5574</fpage><lpage>5585</lpage><pub-id pub-id-type="doi">10.1016/j.csbj.2022.10.002</pub-id><pub-id pub-id-type="pmid">36284708</pub-id>
</element-citation></ref><ref id="B40-vetsci-11-00659"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Andongma</surname><given-names>B.T.</given-names></name>
<name><surname>Huang</surname><given-names>Y.</given-names></name>
<name><surname>Chen</surname><given-names>F.</given-names></name>
<name><surname>Tang</surname><given-names>Q.</given-names></name>
<name><surname>Yang</surname><given-names>M.</given-names></name>
<name><surname>Chou</surname><given-names>S.H.</given-names></name>
<name><surname>Li</surname><given-names>X.</given-names></name>
<name><surname>He</surname><given-names>J.</given-names></name>
</person-group><article-title>In silico design of a promiscuous chimeric multi-epitope vaccine against Mycobacterium tuberculosis</article-title><source>Comput. Struct. Biotechnol. J.</source><year>2023</year><volume>21</volume><fpage>991</fpage><lpage>1004</lpage><pub-id pub-id-type="doi">10.1016/j.csbj.2023.01.019</pub-id><pub-id pub-id-type="pmid">36733703</pub-id>
</element-citation></ref><ref id="B41-vetsci-11-00659"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xiang</surname><given-names>Y.</given-names></name>
<name><surname>Xu</surname><given-names>J.</given-names></name>
<name><surname>McGovern</surname><given-names>B.L.</given-names></name>
<name><surname>Ranzenigo</surname><given-names>A.</given-names></name>
<name><surname>Huang</surname><given-names>W.</given-names></name>
<name><surname>Sang</surname><given-names>Z.</given-names></name>
<name><surname>Shen</surname><given-names>J.</given-names></name>
<name><surname>Diaz-Tapia</surname><given-names>R.</given-names></name>
<name><surname>Pham</surname><given-names>N.D.</given-names></name>
<name><surname>Teunissen</surname><given-names>A.J.P.</given-names></name>
<etal/>
</person-group><article-title>Adaptive multi-epitope targeting and avidity-enhanced nanobody platform for ultrapotent, durable antiviral therapy</article-title><source>Cell</source><year>2024</year><volume>187</volume><fpage>6966</fpage><lpage>6980.e23</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2024.09.043</pub-id><pub-id pub-id-type="pmid">39447570</pub-id>
</element-citation></ref></ref-list></back><floats-group><fig position="float" id="vetsci-11-00659-f001"><label>Figure 1</label><caption><p>Phylogenetic analysis of seven representative PRRSV strains. A Neighbor-Joining (NJ) tree was constructed based on full-length genomic sequences using the p-distance model with 1000 bootstrap replicates to assess the phylogenetic relationships among these strains.</p></caption><graphic xlink:href="vetsci-11-00659-g001" position="float"/></fig><fig position="float" id="vetsci-11-00659-f002"><label>Figure 2</label><caption><p>Design of the finalized multi-epitope vaccine THs-CTLs-NEs. (<bold>A</bold>) Epitope concatenation order and sequence information. (<bold>B</bold>) BepiPred 2.0 assessment of the final NEs, with yellow regions indicating predicted B cell epitopes, while green regions are likely not to correspond to B cell epitopes.</p></caption><graphic xlink:href="vetsci-11-00659-g002" position="float"/></fig><fig position="float" id="vetsci-11-00659-f003"><label>Figure 3</label><caption><p>Predicted secondary structure of the vaccine construct. (<bold>A</bold>) Distribution of &#x003b1;-helices, &#x003b2;-strands, and coils among the amino acid residues. (<bold>B</bold>) Distribution of small non-polar, hydrophobic, polar, and aromatic residues.</p></caption><graphic xlink:href="vetsci-11-00659-g003" position="float"/></fig><fig position="float" id="vetsci-11-00659-f004"><label>Figure 4</label><caption><p>Evaluation of the tertiary structure of THs-CTLs-NEs. (<bold>A</bold>) AlphaFold3-predicted tertiary structure, optimized by GalaxyREFINE. (<bold>B</bold>) Structural assessment parameters, focusing on Ramachandran Favored regions. (<bold>C</bold>) Ramachandran plot with red dots representing residues in Favored, outlier, and rotamer outlier regions. A higher concentration in dark regions indicates better structural quality. (<bold>D</bold>) ProSA-web model quality assessment, where the Z-score evaluates the sample within the typical range for proteins of a similar size.</p></caption><graphic xlink:href="vetsci-11-00659-g004" position="float"/></fig><fig position="float" id="vetsci-11-00659-f005"><label>Figure 5</label><caption><p>Molecular docking of THs-CTLs-NEs with porcine TLR2 and TLR4 via the HDOCK server.</p></caption><graphic xlink:href="vetsci-11-00659-g005" position="float"/></fig><fig position="float" id="vetsci-11-00659-f006"><label>Figure 6</label><caption><p>In silico cloning of the vaccine candidate into PET-28a(+) for prokaryotic expression (<bold>A</bold>) and pFastBac1 for eukaryotic expression (<bold>B</bold>).</p></caption><graphic xlink:href="vetsci-11-00659-g006" position="float"/></fig><fig position="float" id="vetsci-11-00659-f007"><label>Figure 7</label><caption><p>Immune response simulation of THs-CTLs-NEs via the C-ImmSim server across three injections: (<bold>A</bold>) antibody titers, (<bold>B</bold>) cytokine levels, (<bold>C</bold>) total B cell population, (<bold>D</bold>) active B cell population, (<bold>E</bold>) total Th cell population, (<bold>F</bold>) active Th cell population, (<bold>G</bold>) total TC cell population, and (<bold>H</bold>) active TC cell population.</p></caption><graphic xlink:href="vetsci-11-00659-g007" position="float"/></fig><table-wrap position="float" id="vetsci-11-00659-t001"><object-id pub-id-type="pii">vetsci-11-00659-t001_Table 1</object-id><label>Table 1</label><caption><p>Candidate Th epitopes.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Epitope</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Protein</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Sequence</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Length</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Core Sequence</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Epitope<break/>Conservation</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">High<break/>Binders</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">Th1</td><td align="center" valign="middle" rowspan="1" colspan="1">Nsp9</td><td align="left" valign="middle" rowspan="1" colspan="1">RSTPAIVRWFAA<named-content content-type="color:red">H</named-content>LLYELAC&#x02003;&#x02003;(H/N)</td><td align="center" valign="middle" rowspan="1" colspan="1">20</td><td align="center" valign="middle" rowspan="1" colspan="1">VRWFAAHLL</td><td align="center" valign="middle" rowspan="1" colspan="1">6/7</td><td align="center" valign="middle" rowspan="1" colspan="1">12</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Th2</td><td align="center" valign="middle" rowspan="1" colspan="1">Nsp9</td><td align="left" valign="middle" rowspan="1" colspan="1">PNRDRILAALAYHMKA<named-content content-type="color:red">N</named-content>NVSEYYASAAAILMDSCA&#x02003;&#x02003;(N/S)</td><td align="center" valign="middle" rowspan="1" colspan="1">35</td><td align="center" valign="middle" rowspan="1" colspan="1">ILAALAYHM<break/>YYASAAAIL</td><td align="center" valign="middle" rowspan="1" colspan="1">6/7</td><td align="center" valign="middle" rowspan="1" colspan="1">28</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Th3</td><td align="center" valign="middle" rowspan="1" colspan="1">Nsp9</td><td align="left" valign="middle" rowspan="1" colspan="1">VQPLIVYSDDLVLYAES</td><td align="center" valign="middle" rowspan="1" colspan="1">17</td><td align="center" valign="middle" rowspan="1" colspan="1">VYSDDLVLY</td><td align="center" valign="middle" rowspan="1" colspan="1">6/7</td><td align="center" valign="middle" rowspan="1" colspan="1">9</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Th4</td><td align="center" valign="middle" rowspan="1" colspan="1">Nsp11</td><td align="left" valign="middle" rowspan="1" colspan="1">WPDRLV<named-content content-type="color:red">A</named-content>SLRPIHKYSRA&#x02003;&#x02003;(A/T)</td><td align="center" valign="middle" rowspan="1" colspan="1">18</td><td align="center" valign="middle" rowspan="1" colspan="1">VTSLRPIHK</td><td align="center" valign="middle" rowspan="1" colspan="1">6/7</td><td align="center" valign="middle" rowspan="1" colspan="1">12</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Th5</td><td align="center" valign="middle" rowspan="1" colspan="1">Nsp12</td><td align="left" valign="middle" rowspan="1" colspan="1">LACAEFSLDDPV<named-content content-type="color:red">R</named-content>YKHTWGFESDTAYLYEFTG<break/>(R/K)</td><td align="center" valign="middle" rowspan="1" colspan="1">32</td><td align="center" valign="middle" rowspan="1" colspan="1">FESDTAYLY<break/>FSLDDPVRY</td><td align="center" valign="middle" rowspan="1" colspan="1">6/7</td><td align="center" valign="middle" rowspan="1" colspan="1">22</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Th6</td><td align="center" valign="middle" rowspan="1" colspan="1">GP4</td><td align="left" valign="middle" rowspan="1" colspan="1">EFTQRSLVVDHVRLLHFMTPETMR</td><td align="center" valign="middle" rowspan="1" colspan="1">24</td><td align="center" valign="middle" rowspan="1" colspan="1">LVVDHVRLL<break/>LLHFMTPET</td><td align="center" valign="middle" rowspan="1" colspan="1">5/7</td><td align="center" valign="middle" rowspan="1" colspan="1">9</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Th7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GP5</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RYTNFLLDTKG<named-content content-type="color:red">R</named-content>LYRWRSPVI&#x02003;&#x02003;(R/K)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">21</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">FLLDTKGRL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5/7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8</td></tr></tbody></table><table-wrap-foot><fn><p>Note: some predicted Th epitope sequences, each 15 amino acids in length, overlap and have been consolidated into single epitope sequences. Amino acids highlighted in red indicate strain-specific mutations. The count of high-binding peptides indicates the number of integrated sequences, with higher counts suggesting increased MHC II recognition potential.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="vetsci-11-00659-t002"><object-id pub-id-type="pii">vetsci-11-00659-t002_Table 2</object-id><label>Table 2</label><caption><p>Candidate CTL epitopes.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Epitope</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Protein</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Sequence</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Length</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Epitope <break/>Conservation</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">CTL1</td><td align="center" valign="middle" rowspan="1" colspan="1">nsp9</td><td align="center" valign="middle" rowspan="1" colspan="1">GIDGTLWDF</td><td align="center" valign="middle" rowspan="1" colspan="1">9</td><td align="center" valign="middle" rowspan="1" colspan="1">5/7</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">CTL2</td><td align="center" valign="middle" rowspan="1" colspan="1">nsp10</td><td align="center" valign="middle" rowspan="1" colspan="1">ICDAIQPDY</td><td align="center" valign="middle" rowspan="1" colspan="1">9</td><td align="center" valign="middle" rowspan="1" colspan="1">6/7</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">CTL3</td><td align="center" valign="middle" rowspan="1" colspan="1">nsp10</td><td align="center" valign="middle" rowspan="1" colspan="1">EVDLPDGDY</td><td align="center" valign="middle" rowspan="1" colspan="1">9</td><td align="center" valign="middle" rowspan="1" colspan="1">5/7</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">CTL4</td><td align="center" valign="middle" rowspan="1" colspan="1">nsp10</td><td align="center" valign="middle" rowspan="1" colspan="1">MVNTTRVTY</td><td align="center" valign="middle" rowspan="1" colspan="1">9</td><td align="center" valign="middle" rowspan="1" colspan="1">5/7</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">CTL5</td><td align="center" valign="middle" rowspan="1" colspan="1">nsp11</td><td align="center" valign="middle" rowspan="1" colspan="1">KVAHNLGFY</td><td align="center" valign="middle" rowspan="1" colspan="1">9</td><td align="center" valign="middle" rowspan="1" colspan="1">6/7</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">CTL6</td><td align="center" valign="middle" rowspan="1" colspan="1">nsp12</td><td align="center" valign="middle" rowspan="1" colspan="1">GADLAVTPY</td><td align="center" valign="middle" rowspan="1" colspan="1">9</td><td align="center" valign="middle" rowspan="1" colspan="1">6/7</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">CTL7</td><td align="center" valign="middle" rowspan="1" colspan="1">GP2a</td><td align="center" valign="middle" rowspan="1" colspan="1">ASDWFAPRY</td><td align="center" valign="middle" rowspan="1" colspan="1">9</td><td align="center" valign="middle" rowspan="1" colspan="1">6/7</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">CTL8</td><td align="center" valign="middle" rowspan="1" colspan="1">GP2a</td><td align="center" valign="middle" rowspan="1" colspan="1">AIEAETCKY</td><td align="center" valign="middle" rowspan="1" colspan="1">9</td><td align="center" valign="middle" rowspan="1" colspan="1">6/7</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">CTL9</td><td align="center" valign="middle" rowspan="1" colspan="1">GP4</td><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>RTAIGTPVY</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">9</td><td align="center" valign="middle" rowspan="1" colspan="1">6/7</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CTL10</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LSDSGRISY</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6/7</td></tr></tbody></table></table-wrap><table-wrap position="float" id="vetsci-11-00659-t003"><object-id pub-id-type="pii">vetsci-11-00659-t003_Table 3</object-id><label>Table 3</label><caption><p>Candidate neutralizing epitopes.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Epitope</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Protein</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Sequence</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Length</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Strain</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">References</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">NE1</td><td align="center" valign="middle" rowspan="1" colspan="1">GP3</td><td align="center" valign="middle" rowspan="1" colspan="1">QAAAEVYEPGRS</td><td align="center" valign="middle" rowspan="1" colspan="1">12</td><td align="center" valign="middle" rowspan="1" colspan="1">CH-1a</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B22-vetsci-11-00659" ref-type="bibr">22</xref>,<xref rid="B23-vetsci-11-00659" ref-type="bibr">23</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">NE2</td><td align="center" valign="middle" rowspan="1" colspan="1">GP3</td><td align="center" valign="middle" rowspan="1" colspan="1">QAAAEILEPGKS</td><td align="center" valign="middle" rowspan="1" colspan="1">12</td><td align="center" valign="middle" rowspan="1" colspan="1">JXA1</td><td align="center" valign="middle" rowspan="1" colspan="1">N/A</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">NE3</td><td align="center" valign="middle" rowspan="1" colspan="1">GP3</td><td align="center" valign="middle" rowspan="1" colspan="1">QAATEIYEPGRS</td><td align="center" valign="middle" rowspan="1" colspan="1">12</td><td align="center" valign="middle" rowspan="1" colspan="1">VR-2332</td><td align="center" valign="middle" rowspan="1" colspan="1">N/A</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">NE4</td><td align="center" valign="middle" rowspan="1" colspan="1">GP3</td><td align="center" valign="middle" rowspan="1" colspan="1">QAARQRLEPGRN</td><td align="center" valign="middle" rowspan="1" colspan="1">12</td><td align="center" valign="middle" rowspan="1" colspan="1">LV</td><td align="center" valign="middle" rowspan="1" colspan="1">N/A</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">NE5</td><td align="center" valign="middle" rowspan="1" colspan="1">GP3</td><td align="center" valign="middle" rowspan="1" colspan="1">QAAAQILEPGGS</td><td align="center" valign="middle" rowspan="1" colspan="1">12</td><td align="center" valign="middle" rowspan="1" colspan="1">NADC30</td><td align="center" valign="middle" rowspan="1" colspan="1">N/A</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">NE6</td><td align="center" valign="middle" rowspan="1" colspan="1">GP3</td><td align="center" valign="middle" rowspan="1" colspan="1">QAAAQILEPGRS</td><td align="center" valign="middle" rowspan="1" colspan="1">12</td><td align="center" valign="middle" rowspan="1" colspan="1">RFLP_1-4-4</td><td align="center" valign="middle" rowspan="1" colspan="1">N/A</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">NE7</td><td align="center" valign="middle" rowspan="1" colspan="1">GP3</td><td align="center" valign="middle" rowspan="1" colspan="1">QAAAQIYEPGRS</td><td align="center" valign="middle" rowspan="1" colspan="1">12</td><td align="center" valign="middle" rowspan="1" colspan="1">NADC34</td><td align="center" valign="middle" rowspan="1" colspan="1">N/A</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">NE8</td><td align="center" valign="middle" rowspan="1" colspan="1">GP5</td><td align="center" valign="middle" rowspan="1" colspan="1">SSHLQLIYNLT</td><td align="center" valign="middle" rowspan="1" colspan="1">11</td><td align="center" valign="middle" rowspan="1" colspan="1">VR-2332<break/>RFLP_1-4-4<break/>NADC30<break/>NADC34</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B24-vetsci-11-00659" ref-type="bibr">24</xref>,<xref rid="B25-vetsci-11-00659" ref-type="bibr">25</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">NE9</td><td align="center" valign="middle" rowspan="1" colspan="1">GP5</td><td align="center" valign="middle" rowspan="1" colspan="1">SSTYQYIYNLT</td><td align="center" valign="middle" rowspan="1" colspan="1">11</td><td align="center" valign="middle" rowspan="1" colspan="1">LV</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B26-vetsci-11-00659" ref-type="bibr">26</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">NE10</td><td align="center" valign="middle" rowspan="1" colspan="1">GP5</td><td align="center" valign="middle" rowspan="1" colspan="1">SSHIQLIYNLT</td><td align="center" valign="middle" rowspan="1" colspan="1">11</td><td align="center" valign="middle" rowspan="1" colspan="1">JXA1</td><td align="center" valign="middle" rowspan="1" colspan="1">N/A</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">NE11</td><td align="center" valign="middle" rowspan="1" colspan="1">GP5</td><td align="center" valign="middle" rowspan="1" colspan="1">SSHFQLIYNLT</td><td align="center" valign="middle" rowspan="1" colspan="1">11</td><td align="center" valign="middle" rowspan="1" colspan="1">CH-1a</td><td align="center" valign="middle" rowspan="1" colspan="1">N/A</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">NE12</td><td align="center" valign="middle" rowspan="1" colspan="1">GP5</td><td align="center" valign="middle" rowspan="1" colspan="1">WSFADGN</td><td align="center" valign="middle" rowspan="1" colspan="1">7</td><td align="center" valign="middle" rowspan="1" colspan="1">LV</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B27-vetsci-11-00659" ref-type="bibr">27</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NE13</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GP4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GVSAAQEKISFG</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B28-vetsci-11-00659" ref-type="bibr">28</xref>,<xref rid="B29-vetsci-11-00659" ref-type="bibr">29</xref>,<xref rid="B30-vetsci-11-00659" ref-type="bibr">30</xref>]</td></tr></tbody></table></table-wrap></floats-group></article>